Home    Back

Fexinidazole    (DrugBank: Fexinidazole)

1 disease
IDDisease name (Link within this page)Number of trials
65Primary immunodeficiency9

65. Primary immunodeficiency    [ 413 clinical trials,   581 drugs,   (DrugBank: 97 drugs),   68 drug target genes,   202 drug target pathways]
Searched query = "Primary immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase deficiency", "CD8 deficiency", "ZAP-70 deficiency", "MHC class I deficiency", "MHC class II deficiency", "Combined immunodeficiency", "Wiskott-Aldrich syndrome", "Telangiectasia ataxia", "Nijmegen breakage syndrome", "Bloom syndrome", "Immunodeficiency, centromere region instability, facial anomalies syndrome", "ICF syndrome", "PMS2 deficiency", "Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome", "RIDDLE syndrome", "Schimke syndrome", "Netherton syndrome", "Thymic hypoplasia", "DiGeorge syndrome", "22q11.2 deletion syndrome", "Hyper-IgE syndrome", "Hepatic venoocclusive immunodeficiency", "Immunodeficiency with central hepatic vein atresia", "Dyskeratosis congenita", "X-linked agammaglobulinaemia", "Common variable immunodeficiency", "Hyper-IgM syndrome", "Isolated IgG subclass deficiency", "Selective IgA deficiency", "Specific antibody production deficiency", "Infant transient hypogammaglobulinemia", "Chédiak-Higashi syndrome", "Chediak-Higashi syndrome", "X-linked lymphoproliferative syndrome", "SAP deficiency", "SH2D1A/SLAM-associated protein deficiency", "XIAP deficiency", "X-linked inhibitor of apoptosis deficiency", "Autoimmune lymphoproliferative syndrome", "ALPS", "Familial hemophagocytic syndrome", "Perforin deficiency", "Munc13-4 deficiency", "Syntaxin 11 deficiency", "Munc18-2 deficiency", "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy", "APECED", "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", "IPEX syndrome", "CD25 deficiency", "ITCH deficiency", "Primary phagocytic dysfunction", "Severe congenital neutropenia", "Cyclic neutropenia", "Hermanskyi-Pudlak syndrome type 2", "Hermanskyi-Pudlak syndrome 2", "Griscelli syndrome type 2", "Griscelli syndrome 2", "p14 deficiency", "Warts, hypogammaglobulinemia, infections, myelokathexis syndrome", "WHIM syndrome", "Glycogen storage disease type Ib", "Leukocyte adhesion deficiency", "Shwachman-Diamond syndrome", "Chronic granulomatous disease", "Myeloperoxidase deficiency", "Mendelian susceptibility to mycobacterial disease", "MSMD", "Anhidrotic ectodermal dysplasia with immunodeficiency", "EDA-ID", "Interleukin-1 receptor-associated kinase-4 deficiency", "IRAK4 deficiency", "IMyD88 deficiency", "Chronic mucocutaneous candidiasis", "Epidermodysplasia verruciformis", "Herpes simplex encephalitis", "Caspase recruitment domain family member 9 deficiency", "CARD9 deficiency", "Trypanosomiasis", "Congenital complement deficiency", "C1q deficiency", "CC1r deficiency", "CC1s deficiency", "CC2 deficiency", "CC3 deficiency", "CC4 deficiency", "CC5 deficiency", "CC6 deficiency", "CC7 deficiency", "CC8 deficiency", "CC9 deficiency", "Factor D deficiency", "Properdin deficiency", "Factor I deficiency", "Factor H deficiency", "MASP1 deficiency", "3MC syndrome", "Mannose-binding protein-associated serine protease 2 deficiency", "MASP2 deficiency", "FCN3", "Hereditary angioedema type 1", "Hereditary angioedema type I", "C1 inhibitor deficiency type 1", "C1 inhibitor deficiency type I", "Hereditary angioedema type 2", "Hereditary angioedema type II", "C1 inhibitor deficiency type 2", "C1 inhibitor deficiency type II", "Hereditary angioedema type 3", "Hereditary angioedema type III", "C1 inhibitor deficiency type 3", "C1 inhibitor deficiency type III"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 413 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03974178
(ClinicalTrials.gov)		September 29, 201923/5/2019Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei RhodesienseEfficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical TrialTrypanosoma Brucei Rhodesiense; InfectionDrug: FexinidazoleDrugs for Neglected DiseasesEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Recruiting6 YearsN/AAll50Phase 2;Phase 3Malawi;Uganda
2NCT03025789
(ClinicalTrials.gov)		November 17, 201611/11/2016Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any StageAn Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any StageTrypanosomiasis, African;Sleeping Sickness;Trypanosomiasis; GambianDrug: FexinidazoleDrugs for Neglected DiseasesSanofiActive, not recruiting6 YearsN/AAll174Phase 3Congo, The Democratic Republic of the;Guinea
3NCT02571062
(ClinicalTrials.gov)		March 201524/6/2015Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market FormulationA Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed ConditionTrypanosomiasis, AfricanDrug: FexinidazoleDrugs for Neglected DiseasesNULLCompleted18 Years45 YearsMale30Phase 1France
4NCT02498782
(ClinicalTrials.gov)		July 201420/8/2014Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas DiseasePhase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease.Chagas Disease;Trypanosomiasis, South American;South American Trypanosomiasis;Disease, ChagasDrug: Fexinidazole;Drug: PlaceboDrugs for Neglected DiseasesNULLRecruiting18 Years50 YearsBoth140Phase 2Bolivia
5NCT02184689
(ClinicalTrials.gov)		May 3, 201419/6/2014Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal StudyEfficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal StudyHuman African Trypanosomiasis (HAT)Drug: fexinidazoleDrugs for Neglected DiseasesNULLCompleted6 Years14 YearsAll125Phase 2;Phase 3Congo, The Democratic Republic of the
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT02169557
(ClinicalTrials.gov)		April 30, 201415/5/2014Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal StudyEfficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal StudyHuman African Trypanosomiasis (HAT)Drug: FexinidazoleDrugs for Neglected DiseasesNULLCompleted15 YearsN/AAll230Phase 2;Phase 3Congo, The Democratic Republic of the
7NCT01685827
(ClinicalTrials.gov)		October 201212/9/2012Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label StudyHuman African Trypanosomiasis (HAT);Sleeping SicknessDrug: Fexinidazole;Drug: Nifurtimox;Drug: EflornithineDrugs for Neglected DiseasesNULLCompleted15 YearsN/AAll394Phase 2;Phase 3Central African Republic;Congo, The Democratic Republic of the;Congo
8NCT01483170
(ClinicalTrials.gov)		September 201129/11/2011Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With FoodDouble-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.Trypanosomiasis, AfricanDrug: Tablets Fexinidazole;Drug: PlaceboDrugs for Neglected DiseasesNULLTerminated18 Years45 YearsMale30Phase 1France
9NCT00982904
(ClinicalTrials.gov)		September 200922/9/2009Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the FexinidazoleRandomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male VolunteersHuman African TrypanosomiasisDrug: Fexinidazole/PlaceboDrugs for Neglected DiseasesSanofiCompleted18 Years45 YearsMale108Phase 1France

Back to top